Shanghai Labway Clinical Laboratory Co Ltd
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, precision medicine, CRO, and sample bank laboratory services; scientific research technology and testing… Read more
Shanghai Labway Clinical Laboratory Co Ltd (301060) - Total Assets
Latest total assets as of September 2025: CN¥2.43 Billion CNY
Based on the latest financial reports, Shanghai Labway Clinical Laboratory Co Ltd (301060) holds total assets worth CN¥2.43 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Labway Clinical Laboratory Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Shanghai Labway Clinical Laboratory Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanghai Labway Clinical Laboratory Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Labway Clinical Laboratory Co Ltd's total assets of CN¥2.43 Billion consist of 76.2% current assets and 23.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 31.6% |
| Accounts Receivable | CN¥823.17 Million | 31.4% |
| Inventory | CN¥306.09 Million | 11.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥24.45 Million | 0.9% |
| Goodwill | CN¥7.66 Million | 0.3% |
Asset Composition Trend (2013–2024)
This chart illustrates how Shanghai Labway Clinical Laboratory Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Labway Clinical Laboratory Co Ltd's current assets represent 76.2% of total assets in 2024, a decrease from 89.5% in 2013.
- Cash Position: Cash and equivalents constituted 31.6% of total assets in 2024, up from 15.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 31.4% of total assets.
Shanghai Labway Clinical Laboratory Co Ltd Competitors by Total Assets
Key competitors of Shanghai Labway Clinical Laboratory Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Shanghai Labway Clinical Laboratory Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Shanghai Labway Clinical Laboratory Co Ltd generates 0.66x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shanghai Labway Clinical Laboratory Co Ltd is currently not profitable relative to its asset base.
Shanghai Labway Clinical Laboratory Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.08 | 3.45 | 7.51 |
| Quick Ratio | 2.54 | 2.93 | 6.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.24 Billion | CN¥ 1.43 Billion | CN¥ 1.01 Billion |
Shanghai Labway Clinical Laboratory Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Labway Clinical Laboratory Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.70 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -12.2% |
| Total Assets | CN¥2.62 Billion |
| Market Capitalization | $226.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Labway Clinical Laboratory Co Ltd's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Labway Clinical Laboratory Co Ltd's assets decreased by 12.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Labway Clinical Laboratory Co Ltd (2013–2024)
The table below shows the annual total assets of Shanghai Labway Clinical Laboratory Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.62 Billion | -12.17% |
| 2023-12-31 | CN¥2.99 Billion | -20.28% |
| 2022-12-31 | CN¥3.75 Billion | +77.96% |
| 2021-12-31 | CN¥2.11 Billion | +43.08% |
| 2020-12-31 | CN¥1.47 Billion | +5.18% |
| 2019-12-31 | CN¥1.40 Billion | -3.06% |
| 2018-12-31 | CN¥1.44 Billion | +8.51% |
| 2017-12-31 | CN¥1.33 Billion | +40.90% |
| 2016-12-31 | CN¥943.94 Million | +66.85% |
| 2015-12-31 | CN¥565.75 Million | +22.12% |
| 2014-12-31 | CN¥463.27 Million | +40.67% |
| 2013-12-31 | CN¥329.33 Million | -- |